Drugs / STRO-004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07227168 | Nov 2025 → Dec 2027 expected | cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer +5 | Sutro Biopharma, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-21 | Sutro Biopharma, Inc. | Results AACR Annual Meeting 2026 – Presentation and Posters sutrobio.com ↗
STRO-004, a Next-Generation Tissue Factor (TF)-Targeted DAR8-Exatecan ADC, Demonstrates Superior Efficacy Across TF-Expressing Solid Tumors in a Comprehensive Single-Mouse PDX Trial |
| 2025-11-06 | Sutro Biopharma, Inc. | Regulatory Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights sutrobio.com ↗
STRO-004, our Tissue Factor ADC, has received IND clearance ahead of our projections and remains on track to enter the clinic this year, backed by compelling preclinical data that highlight its strong safety profile and potential best-in-class differentiation. |
| 2025-04-28 | Sutro Biopharma, Inc. | Results Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025 sutrobio.com ↗
In preclinical studies, STRO-004 consistently demonstrated potent, dose-dependent anti-tumor activity and a favorable safety profile across all tested doses. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-21 | Sutro Biopharma, Inc. | AACR Annual Meeting 2026 – Presentation and Posters sutrobio.com ↗ |
| 2025-12-03 | Sutro Biopharma, Inc. | Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors sutrobio.com ↗ |
| 2025-11-06 | Sutro Biopharma, Inc. | Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights sutrobio.com ↗ |
| 2025-04-28 | Sutro Biopharma, Inc. | Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025 sutrobio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STRO-004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07227168 ↗ |
| Route | Intravenous | “IV Infusion” NCT07227168 ↗ |